StonvexLoading…
StonvexStonvexStonvexCore line items from ZYME's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.41M | $105.97M | $103.45M | $75.84M |
Operating Income | $-47.12M | $-92.55M | $-48.40M | $-26.29M |
Net Income | $-44.16M | $-81.13M | $-39.92M | $2.32M |
EPS (Diluted) | $-0.59 | $-1.08 | $-0.53 | $-0.27 |
Total Assets | $478.21M | $346.53M | $397.27M | $408.38M |
Total Liabilities | $314.63M | $78.03M | $77.20M | $73.88M |
Cash & Equivalents | $244.28M | $41.16M | $64.83M | $98.25M |
Free Cash Flow OCF − CapEx | $-45.93M | $-34.53M | $-23.69M | $8.14M |
Shares Outstanding | 73.10M | 74.64M | 75.14M | 74.85M |